



aimovig[®]
erenumab

Neuroscience

AIMOVIG® (erenumab)

[Prescribing information](#)



Cosentyx[®]
secukinumab

[Dermatology](#)

Cosentyx® (secukinumab)

[GB Prescribing information](#)

[NI Prescribing information](#)



Cosentyx[®]
secukinumab

[Rheumatology](#)

Cosentyx® (secukinumab)

[GB Prescribing information](#)

[NI Prescribing information](#)



Entresto®
sacubitril/valsartan

Cardio-metabolic

ENTRESTO® (sacubitril/valsartan)

[Prescribing information](#)



FABHALTA® ▼
iptacopan

[Haematology](#)

FABHALTA® ▼ (iptacopan)

[GB Prescribing information](#)

[NI Prescribing information](#)

ILARIS®
(canakinumab)
150 mg subcutaneous injection

Immunology

ILARIS® (canakinumab)

[Prescribing Information](#)



Haematology

JAKAVI® (ruxolitinib)

[Prescribing information](#)



Neuroscience

KESIMPTA®▼ (ofatumumab)

[Prescribing information](#)



Oncology

KISQALI® (ribociclib)

[Prescribing information](#)



LEQVIO® ▼
inclisiran

Cardio-metabolic

LEQVIO®▼ (inclisiran)

[Prescribing information](#)



MAYZENT® ▼
siponimod

Neuroscience

MAYZENT®▼ (siponimod)

[Prescribing information](#)



Sandostatin® LAR®
octreotide / IM INJECTION

Oncology

SANDOSTATIN® LAR® (octreotide acetate)

[Prescribing information](#)



[Haematology](#)

SCEMBLIX®▼ (asciminib)

[GB Prescribing information](#)

[NI Prescribing information](#)



Oncology

TAFINLAR® (dabrafenib) + **MEKINIST**® (trametinib) in melanoma

[Prescribing information](#)



Oncology

TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in Non-Small Cell Lung Cancer (NSCLC)

[Prescribing information](#)

The logo for Xolair, featuring the word 'Xolair' in a large, bold, purple sans-serif font. A stylized purple and white graphic of a hand holding a pen is positioned above the 'i' in 'Xolair'. A thin purple line arches over the top of the word. Below 'Xolair' is the word 'omalizumab' in a smaller, italicized, purple sans-serif font. A registered trademark symbol (®) is located to the right of 'Xolair'.

Xolair[®]
omalizumab

Dermatology

XOLAIR® (omalizumab)

[Prescribing information](#)

The logo for Xolair, identical to the one above, featuring the word 'Xolair' in a large, bold, purple sans-serif font with a stylized hand holding a pen above the 'i', a thin purple arch above the word, and 'omalizumab' in a smaller, italicized, purple sans-serif font below it. A registered trademark symbol (®) is to the right of 'Xolair'.

Xolair[®]
omalizumab

Respiratory and Inflammation

Xolair® (omalizumab)

[Prescribing information](#)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL: <https://www.pro.novartis.com/uk-en/medicines>